Categories: All postsCannabis

Aurora Cannabis is a long-term leader in the cannabis sector, says GMP Securities

Ahead of fiscal third quarter earnings from Canadian cannabis play Aurora Cannabis (Aurora Cannabis Stock Quote, Chart TSX:ACB), GMP Securities analyst Martin Landry is holding steady with his rating, saying that Aurora is positioned to be a leader in the domestic and international markets.

In an equity research update to clients on Monday, Landry says that low sales volumes reported by Health Canada in the January and February rec cannabis channel are cause for a reduction in his revenue forecasts for Aurora, which is expected to report its Q3 fiscal 2019 on May 14. He is now calling for a Q3 top line of $74 million instead of $91 million.

As for the supply shortages being experienced across the country, Landry says that inventory availability at online stores improved between the calendar fourth quarter of 2018 and this year’s Q1, which could mean that provinces will begin to lift their caps on retail licenses in the near term, allowing for a boost in sales growth.

Landry thinks that Aurora is likely to have its first-ever positive EBITDA quarter in its fiscal Q4 and states that based on available data Aurora has been the best performer on inventory availability in Ontario, Quebec and Alberta combined, with over 25 per cent of the share of in-stock SKUs since the start of 2019.

“While we are reducing our near-term forecasts, we continue to believe Aurora is well positioned to be a leader in the cannabis market domestically and abroad over the long-term. Our target is based on a DCF assuming: (1) a 7.5 per cent discount rate, (2) average market share of the domestic recreational market of 23 per cent, and (3) EBITDA margins of 36 per cent,” says Landry.

The analyst is calling for fiscal 2019 (year end June 30) revenue and EBITDA of $$289.7 million and negative $109.6 million, respectively (previously $34.5 million and negative $99.2 million, respectively). Landry is maintaining his “Buy” rating and $15.00 target, which represents a projected return of 27.1 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: acb
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

4 days ago